Clinical Trial Update: Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a first-line combination of raltegravir, emtricitabine, and tenofovir in HIV-2 infection; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-2 Infection

Drugs mentioned

• Emtriva (emtricitabine)
• Isentress (Raltegravir)
• Viread (tenofovir disoproxil fumarate)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: HIV-2 Infection | Phase 2 | Status: COMPLETED | Results posted: 2018-07-20